Category Archives: Patently BIOtech

USPTO Issues New Myriad Guidance

Kaylee_dna_115x76

On Tuesday, December 16 the United States Patent and Trademark Office issued a revised guidance on subject matter eligibility under § 101 in light of recent Supreme Court Decisions in Alice v. CLS Bank, Mayo, and Myriad. These new guidelines are a response to extensive feedback provided from industry leaders and inventors over the last several months. (BIO provided both initial and supplemental comments on the Office’s March Subject Matter Eligibility Guidance). Public comments on the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , ,

Patently Biotech’s Top Articles of 2014

shutterstock_26191726

It’s been a whirlwind year for IP. From international trade negotiations, to revised PTO guidelines and dropping patent case stats, intellectual property is on the brain and in the news. Here are Patently Biotech’s top blog posts of 2014: TPP and IP: The Economic Benefits of a Pacific Trade Agreement Should the USPTO allow the patenting of living organisms? Gene Patent Questions Remain: USPTO Issues Examiner Guidelines Stopped at the Threshold: A New Study Reports Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

BIO Coalition Submits Patent Reform Letter to Congress

medical_research

BIO, alongside a coalition of patent holders and inventors, submitted a letter to the chairmen and ranking members of the House and Senate Judiciary Committees on December 10 regarding potential changes to the patent system. The coalition thanked members of the committee for their work to develop reforms which would prevent harmful patent enforcement practices, and once again reiterated their opposition to any legislation that would weaken the overall patent system. They also asked that Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , ,

Now What is Patentable?

lab_tech

On Tuesday of the Pacific Rim Summit, experts from Knobbe Martens, BIO, and Synthetic Genomics explored the legal, policy and business implications of the Myriad decision, the United States Patent and Trademark Office (PTO) guidance on patentable subject matter under Myriad issued earlier this year, and the revised Myriad guidance expected from the PTO later this year. The Patent Copyright Clause, United States Constitution, Article 1, Section 8: To promote the progress of science and useful arts, by Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Indian Patents Ensure Wide Access to Drugs, Without Raising Prices

patent

Two recent studies on Indian drugs have shown that patent protection does not dramatically increase prices, but does ensure widespread access to life saving therapeutics. This research confirms that a weak patent environment slows drug availability and hinders treatment to many people in need. Data Shows Little Change in Indian Drug Prices after Implementing Stronger Patent System In a new report published by the National Bureau of Economic Research, scholars found that patented drugs did not Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,